Author

Paul R. Chipman

University of FloridaORCID 0000-0003-3652-4087Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:cryo-EM· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

Jane HsiiD· 2 shared Mario MietzschiD· 2 shared ROBERT V. McKENNAiD· 2 shared Ann-Maree Huang· 1 shared Ariana JoseiD· 1 shared Austin R. Nelson· 1 shared Courtnee Eddington· 1 shared Grant J. LoganiD· 1 shared

Activity by Year

2021-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Jane HsiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologyNature CommunicationsPeer-reviewedApr 19, 2025

Structural characterization of antibody-responses from Zolgensma treatment provides the blueprint for the engineering of an AAV capsid suitable for redosing

Mario Mietzsch, Jane Hsi, Austin R. Nelson…·ROBERT V. McKENNA

This study uses cryo-EM to analyze antibodies against AAV9 vectors, identifying residues that enable capsid engineering to avoid neutralization and allow redosing.

15 citationstop 2%

humancryo-EM

𝕏 PostBluesky

Molecular BiologyJournal of VirologyPeer-reviewedJul 21, 2021

Improved Genome Packaging Efficiency of AAV Vectors Using Rep Hybrids

Mario Mietzsch, Courtnee Eddington, Ariana Jose…·Mavis Agbandje‐McKenna

This study improves AAV vector genome packaging efficiency by engineering Rep hybrid proteins, reducing empty capsids and increasing full capsid yields across non-AAV2 serotypes.

50 citations

experimental assay

𝕏 PostBluesky